GlassScriptPhysician profile
Jonathan David Skoner
NPI 1396170619
$9,034.40
in general payments reported to CMS, 2019-2025
9 companies · $6,515 in 2025
The $6,515 reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127 · 2020: $145 · 2021: $74.23 · 2022: $188 · 2023: $880 · 2024: $1,106 · 2025: $6,515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $6,350 · Food and Beverage: $2,150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $6,350.00 |
| Food and Beverage | $2,150.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $7,334.68 | 2022-2025 | Arise, Infuse, Miebo |
| Johnson & Johnson Vision Care, INC. | $587.82 | 2019-2025 | Acuvue |
| Coopervision INC. | $534.28 | 2019-2025 | Misight Contact Lens, Myday Contact Lens, Clariti Contact Lens |
| Alcon Vision LLC | $187.68 | 2021-2025 | Total30, Precision 1, Dailies Total1 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $187.05 | 2020-2021 | |
| Sight Sciences, INC. | $82.39 | 2019 | |
| Oyster Point Pharma, INC. | $56.50 | 2022-2024 | Tyrvaya, Ryzumvi |
| Sun Pharmaceutical Industries INC. | $45.47 | 2023 | Cequa |
| Kala Pharmaceuticals, INC. | $18.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Skoner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.